Visual Perception in Schizophrenia Study

This study is looking at how visual perception works in people with schizophrenia, bipolar disorder, and schizoaffective disorder. It uses a non-invasive test called an EEG (electroencephalography) to measure brain activity related to vision. The main goal is to see if the strength of this brain activity, measured on Day 1, can help us understand these conditions better. You might be able to join if you are between 18 and 65 years old, have good vision, can speak English, and have been diagnosed with schizophrenia, schizoaffective disorder, or schizophreniform disorder. The study is currently unclear on its recruitment status.

Study design: This is an interventional study with a planned enrollment of 84 participants. The study type is not specified (e.g., randomized, single-arm).
What's involved: You would undergo an EEG measure of early cortical visual processing on Day 1.
Compensation: Not stated in the trial record.
Follow-up: Not specified.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

Visual Perception in Schizophrenia

Recruiting

NAAges 18–65InterventionalBasic science

University of Rochester

~84 participants

Updated 2025-11-12 on ClinicalTrials.gov

What's tested:EEG measure of visual processing

At a glance

Recruiting sites

1 of 1 listed site is recruiting right now

RecruitingSuspended, closed, or not yet open

What they're measuring

mean amplitude of EEG visual response

Measured over Day 1

Conditions

Schizophrenia Disorders

Bipolar Disorder

Schizo Affective Disorder

Where it's being run

1 sites across 1 states

New York1

Who to contact

Edmund Lalor, PhD

[email protected]

585-275-3077

Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime

Eligibility criteria

Inclusion

All Subjects

Aged 18-65

20/32 visual acuity or better (using in-house optical correction, if necessary)

An ability to speak English well enough to complete study assessments and to consent to the study

Subjects with Schizophrenia-Spectrum Disorder

Meets DSM-5 diagnostic criteria for schizophrenia, schizoaffective disorder, or schizophreniform disorder as confirmed by the Structured Interview for DSM-5 (SCID-5).

Subjects with Bipolar Disorder

Meets DSM-5 diagnostic criteria for bipolar disorder (type I, II, or unspecified) as confirmed by the Structured Interview for DSM-5 (SCID-5).

Exclusion

All subjects

Presence of characteristics that could impair one's ability to comprehend the nature of the study, provide informed consent, or understand the assessment questions, including the following:

Subject cannot read and understand the instructions well enough to complete the tasks or cannot provide informed consent.

Intellectual impairment (WRAT-5 score \< 70) (at the discretion of experimenter);

Actively intoxicated, as shown via patient self-report or staff report;

Substance use disorder in the past 3 months;

Subject considered high risk for suicidal acts (i.e., active suicidal ideation as determined by clinical interview OR any suicide attempt in 30 days prior to screening);

Subject violence (involving severe/lethal means or violence occurring in prior 6 months) or extreme agitation.

Being in a current manic state

Head injury with loss of consciousness greater than 10 minutes (at the discretion of the experimenter).

Subject has had electroconvulsive therapy (ECT) in the past 8 weeks;

Diagnosed with a neurological condition (tumor, stroke, brain injury) or neurological disorder, including seizure disorders. Diagnosed with pervasive developmental disorder (phone screen or medical records)

Lazy eye or squint or other known ocular pathology

Healthy Control Subjects

Any lifetime psychotic disorder or history of psychiatric hospitalization (self disclosure);

Daily antidepressant, mood stabilizer or antipsychotic medication use in the last 6 months, or benzodiazepine use during the prior 2 days (self-disclosure); iii. First-degree relative(s) with a schizophrenia spectrum disorder (based on subject self-report) or bipolar disorder.

Case-match Control Non-ill Subjects

Any lifetime psychotic disorder (as assessed by SCID/or SSD);

Recurrent depressive episodes or being in a current depressive episode (as assessed by SCID/or SSD)

Persistent threshold psychotic symptoms

History of psychiatric hospitalization;

Daily antidepressant, mood stabilizer or antipsychotic medication use in the last 6 months, or benzodiazepine use during the prior 2 days

First-degree relative(s) with a schizophrenia spectrum disorder (based on subject self-report) or bipolar disorder.

Bipolar Subjects

Persistent threshold psychotic symptoms

What this trial measures

mean amplitude of EEG visual responseDay 1

Trialytics